The 1-, 2-, and 3-year recurrence-free survival (RFS) rates in this subgroup were 54.7%, 39.0%, and 29.3%, respectively.<h4>Conclusion</h4>For patients with initially unresectable CCA, PD-1/PD-L1 inhibitors plus TKIs can successfully downstage the tumor. Here, CD274 is linked to cholangiocarcinoma.